THE ARISING · Markets & Strategy
EU Drug Committee Backs Lilly's Daily Weight-Loss Pill Foundayo
Europe is one step from authorising a once-daily GLP-1 tablet from Eli Lilly for weight loss and type 2 diabetes. The European Medicines Agency's human medicines committee, the CHMP, recommended Foundayo (orforglipron) at its 12–15 October 2026 meeting, according to the agency.
The committee recommended a marketing authorisation for adults, for weight management and for the treatment of type 2 diabetes. Foundayo is an oral GLP-1 receptor agonist taken as one tablet a day. The EMA describes it as an alternative to injectable and other oral GLP-1 receptor agonists. The applicant is Eli Lilly Nederland B.V.
This is a recommendation, not a final approval. The EMA lists the European Commission's decision on Foundayo as pending. Until the Commission acts, the drug cannot be marketed in the EU on the strength of this opinion.
The market implications below are our analysis, not the EMA's findings. The EMA's wording shows that regulators see a place for a daily tablet alongside injections and existing pills. If the Commission confirms the opinion, Lilly could compete for European patients who prefer not to inject. How much share it wins will depend on price, reimbursement and supply. The EMA announcement does not address any of these, and this is the weakest part of our argument.
The wider meeting was favourable for new drugs. The CHMP recommended six new medicines and issued no negative opinions on new medicines this month. For 2026 so far, the EMA's figures show 72 positive and 8 negative opinions on new medicines. Other recommendations included Rasonque (daraxonrasib) for metastatic pancreatic cancer and Fovlussea, a ranibizumab biosimilar for wet age-related macular degeneration and other eye conditions.
What to watch next
The European Commission's decision on Foundayo, and then whether national health systems agree to pay for it. Patients should discuss any questions about GLP-1 treatment with their own clinician.
Arrowhead Reports Its Tau-Silencing Drug Lowers Spinal Fluid Tau by Up to 73% EU Drug Committee Backs Lilly's Daily Weight-Loss Pill Foundayo England's Adult Social Care Workforce Grows at Slowest Rate in Four Years BioAge and Deep Origin Launch Multi-Target AI Drug Discovery Collaboration Neko Health Brings $500 Body Scans to US With 300,000-Person Waitlist